First Time Loading...

Genmab A/S

Watchlist Manager
Genmab A/S
Price: 35.27 USD -0.17% Market Closed
Updated: Oct 1, 2023

Intrinsic Value

Intrinsic Value History
Genmab A/S

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access Genmab A/S's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Valuation Methods

There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.

DCF Value
Discounted Cash Flow

DCF Parameters:
Operating Model
Discount Rate
Forecast Period
Terminal Growth
DCF Input
DCF Input
DCF Input

Fundamental Analysis


Balance Sheet Decomposition
Genmab A/S

Current Assets 29.7B
Cash & Short-Term Investments 24.9B
Receivables 4.8B
Other Current Assets 51m
Non-Current Assets 2.2B
Long-Term Investments 183m
PP&E 1.6B
Intangibles 129m
Other Non-Current Assets 283m
Current Liabilities 2B
Other Current Liabilities 2B
Non-Current Liabilities 1.2B
Long-Term Debt 721m
Other Non-Current Liabilities 509m
Fundamental Scores

GMAB Profitability Score
Profitability Due Diligence

Genmab A/S's profitability score is 74/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Positive Operating Income
Positive Net Income

Genmab A/S's profitability score is 74/100. The higher the profitability score, the more profitable the company is.

GMAB Solvency Score
Solvency Due Diligence

Genmab A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency

Genmab A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GMAB Price Targets Summary
Genmab A/S

Wall Street analysts forecast GMAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GMAB is 110.14 USD with a low forecast of 27.84 USD and a high forecast of 417.65 USD.

Price Target
27.84 USD
21% Downside
Price Target
110.14 USD
212% Upside
Price Target
417.65 USD
1 084% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

GMAB Return Decomposition
Main factors of price return

What is price return decomposition?

GMAB Price
Genmab A/S

1M 1M
6M 6M
1Y 1Y
3Y 3Y
5Y 5Y
10Y 10Y
Annual Price Range
2 514
52w Low
2 455
52w High
3 295
Price Metrics
Average Annual Return 29.22%
Standard Deviation of Annual Returns 32.55%
Max Drawdown -25%
Shares Statistics
Market Capitalization 164B DKK
Shares Outstanding 66 057 100
Percentage of Shares Shorted

Company Profile

Genmab A/S





Market Cap

164B USD

Dividend Yield



Genmab A/S operates as an international biotechnology company. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.


Kalvebod Brygge 43




1 212


Co-Founder, Pres & CEO
Dr. Jan G.J. van de Winkel Ph.D.
Exec. VP & CFO
Mr. Anthony Pagano
Exec. VP & COO
Mr. Anthony Mancini
Exec. VP & Chief Devel. Officer
Dr. Judith V. Klimovsky M.D.
Exec. VP, Chief Medical Officer & Head of Experimental Medicines
Dr. Tahamtan Ahmadi
Director of Protein Production & Chemist and Non-Independent Director
Dr. Mijke Zachariasse Ph.D.
Show More
VP, Head of Global Regulatory Affairs ? Oncology & Non-Independent Director
Dr. Rima Bawarshi Nassar Ph.D.
Sr. Director of Fin. & Accounting
Mr. Peter Ros
Sr. Director, VP & Head of Investor Relations
Mr. Andrew Carlsen
Exec. VP & Chief Legal Officer
Ms. Birgitte Stephensen M.Sc.
Show Less

See Also

Other Stocks
What is the Intrinsic Value of one GMAB stock?

The intrinsic value of one GMAB stock under the Base Case scenario is 31.21 USD.

Is GMAB stock undervalued or overvalued?

Compared to the current market price of 35.27 USD, Genmab A/S is Overvalued by 12%.